20 related articles for article (PubMed ID: 25370853)
1. Predictors of early treatment discontinuation and severe anemia in a Brazilian cohort of hepatitis C patients treated with first-generation protease inhibitors.
Miotto N; Mendes LC; Zanaga LP; Goncales ES; Lazarini MS; Pedro MN; Goncales FL; Stucchi RS; Vigani AG
Braz J Med Biol Res; 2016 Jun; 49(7):. PubMed ID: 27356107
[TBL] [Abstract][Full Text] [Related]
2. Treatment of experienced and naïve patients with hepatitis C: focus on telaprevir.
D'Ambrosio R; Aghemo A; Colombo M
Biologics; 2012; 6():363-70. PubMed ID: 23118525
[TBL] [Abstract][Full Text] [Related]
3. Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy.
Ogawa E; Furusyo N; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
J Hepatol; 2013 Oct; 59(4):667-74. PubMed ID: 23707372
[TBL] [Abstract][Full Text] [Related]
4. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
[TBL] [Abstract][Full Text] [Related]
5. Effects on anemia of drug adjustment in patients with chronic hepatitis C during telaprevir-combined therapy.
Tamori A; Kioka K; Sakaguchi H; Enomoto M; Hai H; Kawamura E; Hagihara A; Fujii H; Uchida-Kobayashi S; Iwai S; Morikawa H; Murakami Y; Kawasaki Y; Tsuruta D; Kawada N
Ann Hepatol; 2015; 14(1):28-35. PubMed ID: 25536639
[TBL] [Abstract][Full Text] [Related]
6. The prospective randomized study on telaprevir at 1500 or 2250 mg with pegylated interferon plus ribavirin in Japanese patients with HCV genotype 1.
Oze T; Hiramatsu N; Yakushijin T; Yamada R; Harada N; Morishita N; Yamada A; Oshita M; Kaneko A; Suzuki K; Inui Y; Tamura S; Yoshihara H; Imai Y; Miyagi T; Yoshida Y; Tatsumi T; Kasahara A; Hayashi N; Takehara T
J Gastroenterol; 2015 Mar; 50(3):313-22. PubMed ID: 24806033
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of telaprevir, pegylated interferon α-2b and ribavirin triple therapy in Japanese patients infected with hepatitis C virus genotype 1b.
Kawaguchi Y; Iwane S; Kumagai T; Yanagita K; Yasutake T; Ide Y; Otsuka T; Eguchi Y; Ozaki I; Akiyama T; Kawazoe S; Mizuta T
Intern Med; 2015; 54(20):2551-60. PubMed ID: 26466688
[TBL] [Abstract][Full Text] [Related]
8. Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders.
Forestier N; Zeuzem S
Liver Int; 2012 Feb; 32 Suppl 1():44-50. PubMed ID: 22212571
[TBL] [Abstract][Full Text] [Related]
9. Adjusting the starting dose of telaprevir according to renal function decreases adverse effects and affects the sustained virological response rate.
Morihara D; Watanabe H; Takata K; Iwashita H; Tsuchiya N; Kunimoto H; Kuno S; Fukunaga A; Yotsumoto K; Tanaka T; Sakurai K; Hirano G; Yokoyama K; Nishizawa S; Yoshikane M; Anan A; Takeyama Y; Kitamura Y; Iwata K; Irie M; Shakado S; Sohda T; Sakisaka S
Eur J Gastroenterol Hepatol; 2015 Jan; 27(1):55-64. PubMed ID: 25370853
[TBL] [Abstract][Full Text] [Related]
10. Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients.
Burney T; Dusheiko G
Expert Rev Anti Infect Ther; 2011 Feb; 9(2):151-60. PubMed ID: 21143041
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]